Cover Image
Market Research Report

Chemotherapy-induced thrombocytopenia (CIT) - Market Insights, Epidemiology, and Market Forecast - 2028

Published by DelveInsight Business Research LLP Product code 915409
Published Content info 128 Pages
Delivery time: 1-2 business days
Price
Back to Top
Chemotherapy-induced thrombocytopenia (CIT) - Market Insights, Epidemiology, and Market Forecast - 2028
Published: November 1, 2019 Content info: 128 Pages
Description

DelveInsight's 'Chemotherapy-induced thrombocytopenia (CIT)-Market Insights, Epidemiology, and Market Forecast-2028' report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Chemotherapy-induced thrombocytopenia in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Chemotherapy-induced thrombocytopenia from 2017 to 2028 segmented by seven major markets.

Thrombocytopenia can be defined as the deficiency of platelets (thrombocytes) that increase the risk of bleeding. Platelets maintain vascular endothelium integrity and control hemorrhage control following small-vessel injury by platelet plug formation and provide a firm, stable, fibrin clot in large injury.

The National Cancer Institute Common Toxicity Criteria defines Chemotherapy-induced thrombocytopenia (CIT) as a platelet count of fewer than 75,000 cells/µL, with the risk of bleeding, complications increase with lower platelet counts. However, there is no standard definition of CIT, it depends mostly on the observed platelet count reduction in clinical settings. It is a frequent complication associated with cancer therapy and the decrease in platelet count persists despite adequate recovery time from prior chemotherapy nadir, in the context of recovery of white cells and red cells.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Chemotherapy-induced thrombocytopenia - Disease Understanding and Diagnosis

CIT is a common hematologic toxicity of myelosuppressive (side effects of some cancer treatments) and ablative therapies (used to destroy abnormal tissues). It is treated on the basis of etiology, severity, and duration of thrombocytopenia. Thrombocytopenia is classified as Idiopathic Thrombocytopenic Purpura, Thrombotic Thrombocytopenic Purpura, Drug-Induced Thrombocytopenia, and others based on etiology.

Diagnosis of thrombocytopenia must be based on medical history, physical exam and the test result of an individual. For the analysis of medical history, the knowledge about the medicines and given treatment with chemo-regimens and general observation of the person, while taking chemotherapy are required. Along with this, the knowledge about the NCI grade adverse events associated with chemo-regimens may be helpful for early identification of CIT and other hematological toxicity.

Chemotherapy-induced thrombocytopenia Epidemiology

The Chemotherapy-induced thrombocytopenia epidemiology division provides insights about historical and current incident pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL).

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Incident cases of CIT and Total Incidence of CIT by Chemotherapeutic Agents) scenario of Chemotherapy-induced thrombocytopenia in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017 to 2028.

According to DelveInsight, the total Incident cases of Chemotherapy-induced thrombocytopenia (CIT) in the 7MM was found to be 302,735 in 2017. The incidence of Chemotherapy-induced thrombocytopenia in the 7MM is expected to increase during the study period of 2017-2028.

Chemotherapy-induced thrombocytopenia Drug Chapters

This segment of the Chemotherapy-induced thrombocytopenia report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Currently, the management of chemotherapy-associated thrombocytopenia often involves treating any other underlying cause of thrombocytopenia by avoiding antibiotics, treating infection, and controlling coagulopathy. The treatment of CIT comprises of dose reductions or treatment delays of chemotherapy, platelet transfusions as a standard treatment choice. Recombinant interleukin-11 (IL-11) (Oprelvekin) is the only available option in pharmacological management. Antifibrinolytic agents, such as epsilon-aminocaproic acid or tranexamic acid are used as off-label.

Detailed chapters of current therapy i.e. Neumega (Wyeth Pharmaceutical) and emerging therapies, such as Avatrombopag (Dova Pharmaceuticals), Romiplostim (Amgen), Eltrombopag (Novartis), and others have also been provided in the report.

Chemotherapy-induced thrombocytopenia Market Outlook

The Chemotherapy-induced thrombocytopenia market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

According to DelveInsight, the market for Chemotherapy-induced thrombocytopenia in 7MM was found to be approximately USD 921.81 Million in 2017.

Chemotherapy-induced thrombocytopenia market size in the United States accounted for 47% of the total market in 2017. The US-led the market in 2017, followed by the EU5 and Japan, respectively. Due to the high incidence of this disease in the region, the Chemotherapy-induced thrombocytopenia treatment market in the US is expected to dominate the market during the forecast period (2019-2028).

Chemotherapy-induced thrombocytopenia Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies, and sales of each drug.

The dynamics of Chemotherapy-induced thrombocytopenia market is anticipated to change in the coming years owing to the expected launch of emerging therapies, such as Avatrombopag (Dova Pharmaceuticals), Romiplostim (Amgen), Eltrombopag (Novartis), and others in the Chemotherapy-induced thrombocytopenia market by 2028.

Chemotherapy-induced thrombocytopenia Report Insights

  • Incident cases of Chemotherapy-induced thrombocytopenia
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Chemotherapy-induced thrombocytopenia Report Key Strengths

  • 10-Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Chemotherapy-induced thrombocytopenia Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Chemotherapy-induced thrombocytopenia market
  • Organize sales and marketing efforts by identifying the best opportunities for Chemotherapy-induced thrombocytopenia market
  • To understand the future market competition in the Chemotherapy-induced thrombocytopenia market

Table of Contents
Product Code: DIMI0686

Table of Contents

1. Key Insights

2. Chemotherapy-induced Thrombocytopenia: Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Chemotherapy-induced Thrombocytopenia in 2017
  • 2.2. Market Share (%) Distribution of Chemotherapy-induced Thrombocytopenia in 2028

3. Disease Overview: Chemotherapy-induced thrombocytopenia (CIT)

  • 3.1. Introduction
  • 3.2. Thrombocytopenia-Classification
  • 3.3. Signs and Symptoms
  • 3.4. Grading System
  • 3.5. Clinical approach to Thrombocytopenia
  • 3.6. Process of Platelet Genesis and Platelet Production
  • 3.7. Pathophysiology
  • 3.8. Biologics with Thrombopoietic Potential
  • 3.9. Diagnosis

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. 7MM Incident Cases of Chemotherapy-induced thrombocytopenia
  • 4.3. Country Wise-Epidemiology of Chemotherapy-induced thrombocytopenia
  • 4.4. United States
    • 4.4.1. Assumptions and Rationale
    • 4.4.2. Incident Cases of Chemotherapy-induced thrombocytopenia in the United States
    • 4.4.3. Incidence of CIT by Chemotherapeutic Agent in the United States
  • 4.5. EU5
  • 4.6. Assumptions and Rationale
  • 4.7. Germany
    • 4.7.1. Incident Cases of Chemotherapy-induced thrombocytopenia in Germany
    • 4.7.2. Incidence of CIT by Chemotherapeutic Agent in Germany
  • 4.8. France
    • 4.8.1. Incident Cases of Chemotherapy-induced thrombocytopenia in France
    • 4.8.2. Incidence of CIT by Chemotherapeutic Agent in France
  • 4.9. Italy
    • 4.9.1. Incident Cases of Chemotherapy-induced thrombocytopenia in Italy
    • 4.9.2. Incidence of CIT by Chemotherapeutic Agent in Italy
  • 4.10. Spain
    • 4.10.1. Incident Cases of Chemotherapy-induced thrombocytopenia in Spain
    • 4.10.2. Incidence of CIT by Chemotherapeutic Agent in Spain
  • 4.11. United Kingdom
    • 4.11.1. Incident Cases of Chemotherapy-induced thrombocytopenia in the UK
    • 4.11.2. Incidence of CIT by Chemotherapeutic Agent in the UK
  • 4.12. Japan
    • 4.12.1. Assumptions and Rationale
    • 4.12.2. Incident Cases of Chemotherapy-induced thrombocytopenia in Japan
    • 4.12.3. Incidence of CIT by Chemotherapeutic Agent in Japan

5. Current Treatment Practices

  • 5.1. Platelet Transfusion for Patients with Cancer- Clinical Practice Guidelines of the American Society of Clinical Oncology
    • 5.1.1. ACSO-2017 Updated Guidelines
  • 5.2. Clinical Practice Guidelines: American Association of Blood Banks (AABB) for Platelet Transfusion

6. Unmet Needs

7. Marketed drugs

  • 7.1. Neumega: Wyeth Pharmaceutical
    • 7.1.1. Drug Description
    • 7.1.2. Regulatory Milestones
    • 7.1.3. Other Developmental Activities
    • 7.1.4. Safety and Efficacy
    • 7.1.5. Product Profile

8. Emerging Therapies

  • 8.1. Key cross competition- Emerging Therapies
  • 8.2. Avatrombopag: Dova Pharmaceuticals
    • 8.2.1. Drug Description
    • 8.2.2. Other Developmental Activities
    • 8.2.3. Clinical Development
    • 8.2.4. Safety and Efficacy
    • 8.2.5. Product Profile
  • 8.3. Romiplostim: Amgen
    • 8.3.1. Drug Description
    • 8.3.2. Other Developmental Activities
    • 8.3.3. Clinical Development
    • 8.3.4. Safety and Efficacy
    • 8.3.5. Product Profile
  • 8.4. Eltrombopag: Novartis
    • 8.4.1. Drug Description
    • 8.4.2. Other Developmental Activities
    • 8.4.3. Clinical development
    • 8.4.4. Safety and Efficacy
    • 8.4.5. Product Profile

9. Chemotherapy-induced thrombocytopenia: 7 Major Market Analysis

  • 9.1. Key Findings
  • 9.2. Market Size of Chemotherapy-induced thrombocytopenia in 7MM

10. Market Outlook by Country

11. United States: Market Outlook

  • 11.1. United States Market Size
    • 11.1.1. Total Market Size of Chemotherapy-induced thrombocytopenia
    • 11.1.2. Market Size of Chemotherapy-induced thrombocytopenia (CIT) by Therapies

12. EU-5 Countries: Market Outlook

  • 12.1. Germany
    • 12.1.1. Total Market size of Chemotherapy-induced thrombocytopenia
    • 12.1.2. Market Size of Chemotherapy-induced thrombocytopenia (CIT) by Therapies
  • 12.2. France
    • 12.2.1. Total Market Size of Chemotherapy-induced thrombocytopenia
    • 12.2.2. Market Size of Chemotherapy-induced thrombocytopenia (CIT) by Therapies
  • 12.3. Italy
    • 12.3.1. Total Market Size of Chemotherapy-induced thrombocytopenia
    • 12.3.2. Market Size of Chemotherapy-induced thrombocytopenia (CIT) by Therapies
  • 12.4. Spain
    • 12.4.1. Total Market Size of Chemotherapy-induced thrombocytopenia
    • 12.4.2. Market Size of Chemotherapy-induced thrombocytopenia (CIT) by Therapies
  • 12.5. United Kingdom
    • 12.5.1. Total Market Size of Chemotherapy-induced thrombocytopenia
    • 12.5.2. Market Size of Chemotherapy-induced thrombocytopenia (CIT) by Therapies
  • 12.6. Japan: Market Outlook
    • 12.6.1. Total Market Size of Chemotherapy-induced thrombocytopenia
    • 12.6.2. Market Size of Chemotherapy-induced thrombocytopenia (CIT) by Therapies

13. Market Drivers

14. Market Barriers

15. Appendix

16. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

List of Tables

  • Table 1 WHO Bleeding Scale
  • Table 2 Summary of the Modified WHO Bleeding Scale
  • Table 3 The Bleeding Severity Measurement Scale by Webert et al. (2012)
  • Table 4 Differential diagnosis of Thrombocytopenia according to clinical scenario
  • Table 5 Incident Cases of Chemotherapy-induced thrombocytopenia in 7MM (2017-2028)
  • Table 6 Incident Cases of Chemotherapy-induced thrombocytopenia in the US (2017-2028)
  • Table 7 Incidence of CIT by Chemotherapeutic Agent in the United States (2017-2028)
  • Table 8 Incident Cases of Chemotherapy-induced thrombocytopenia in Germany (2017-2028)
  • Table 9 Incidence of CIT by Chemotherapeutic Agent in Germany (2017-2028)
  • Table 10 Incident Cases of Chemotherapy-induced thrombocytopenia in France (2017-2028)
  • Table 11 Incidence of CIT by Chemotherapeutic Agent in France (2017-2028)
  • Table 12 Incident Cases of Chemotherapy-induced thrombocytopenia in Italy (2017-2028)
  • Table 13 Incidence of CIT by Chemotherapeutic Agent in Italy (2017-2028)
  • Table 14 Incident Cases of Chemotherapy-induced thrombocytopenia in Spain (2017-2028)
  • Table 15 Incidence of CIT by Chemotherapeutic Agent in Spain (2017-2028)
  • Table 16 Incident Cases of Chemotherapy-induced thrombocytopenia in the UK (2017-2028)
  • Table 17 Incidence of CIT by Chemotherapeutic Agent in the UK (2017-2028)
  • Table 18 Incident Cases of Chemotherapy-induced thrombocytopenia in Japan (2017-2028)
  • Table 19 Incidence of CIT by Chemotherapeutic Agent in Japan (2017-2028)
  • Table 20 Summary of 2001 Guidelines
  • Table 21 Summary of 2017 Guidelines
  • Table 22 Emerging Drugs Analysis
  • Table 23 Avatrombopag, Clinical Trial Description, 2019
  • Table 24 Romiplostim, Clinical Trial Description, 2019
  • Table 25 Eltrombopag, Clinical Trial Description, 2019
  • Table 26 7 MM Market Size of CIT in USD Million (2017-2028)
  • Table 27 United States Market Size of CIT in USD Million (2017-2028)
  • Table 28 Market Size of CIT by Therapies in USD Million (2017-2028)
  • Table 29 Germany Market Size of CIT in USD Million (2017-2028)
  • Table 30 Market Size of CIT by Therapies in USD Million (2017-2028)
  • Table 31 France Market Size of CIT in USD Million (2017-2028)
  • Table 32 Market Size of CIT by Therapies in USD Million (2017-2028)
  • Table 33 Italy Market Size of CIT in USD Million (2017-2028)
  • Table 34 Market Size of CIT by Therapies in USD Million (2017-2028)
  • Table 35 Spain Market Size of CIT in USD Million (2017-2028)
  • Table 36 Market Size of CIT by Therapies in USD Million (2017-2028)
  • Table 37 United Kingdom Market Size of CIT in USD Million (2017-2028)
  • Table 38 Market Size of CIT by Therapies in USD Million (2017-2028)
  • Table 39 Japan Market Size of CIT in USD Million (2017-2028)
  • Table 40 Market Size of CIT by Therapies in USD Million (2017-2028)

List of Figures

  • Figure 1: Classification of Thrombocytopenia
  • Figure 2: NCI Grading of Thrombocytopenia
  • Figure 3: The Production of Platelets from Bone Marrow Stem Cells
  • Figure 4: Incident Cases of Chemotherapy-induced thrombocytopenia in 7MM (2017-2028)
  • Figure 5: Incident Cases of Chemotherapy-induced thrombocytopenia in the US (2017-2028)
  • Figure 6: Incidence of CIT by Chemotherapeutic Agent in the United States (2017-2028)
  • Figure 7: Incident Cases of Chemotherapy-induced thrombocytopenia in Germany (2017-2028)
  • Figure 8: Incidence of CIT by Chemotherapeutic Agent in Germany (2017-2028)
  • Figure 9: Incident Cases of Chemotherapy-induced thrombocytopenia in France (2017-2028)
  • Figure 10: Incidence of CIT by Chemotherapeutic Agent in France (2017-2028)
  • Figure 11: Incident Cases of Chemotherapy-induced thrombocytopenia in Italy (2017-2028)
  • Figure 12: Incidence of CIT by Chemotherapeutic Agent in Italy (2017-2028)
  • Figure 13: Incident Cases of Chemotherapy-induced thrombocytopenia in Spain (2017-2028)
  • Figure 14: Incidence of CIT by Chemotherapeutic Agent in Spain (2017-2028)
  • Figure 15: Incident Cases of Chemotherapy-induced thrombocytopenia in the UK (2017-2028)
  • Figure 16: Incidence of CIT by Chemotherapeutic Agent in the UK (2017-2028)
  • Figure 17: Incident Cases of Chemotherapy-induced thrombocytopenia in Japan (2017-2028)
  • Figure 18: Incidence of CIT by Chemotherapeutic Agent in Japan (2017-2028)
  • Figure 19: Unmet Needs
  • Figure 20: 7 Major Market Size of Chemotherapy-induced thrombocytopenia in USD Million (2017-2028)
  • Figure 21: Market Size of CIT in the US, USD Millions (2017-2028)
  • Figure 22: Market Size of CIT by Therapies in USD Million (2017-2028)
  • Figure 23: Market Size of CIT in Germany, USD Millions (2017-2028)
  • Figure 24: Market Size of CIT by Therapies in USD Million (2017-2028)
  • Figure 25: Market Size of CIT in France USD Millions (2017-2028)
  • Figure 26: Market Size of CIT by Therapies in USD Million (2017-2028)
  • Figure 27: Market Size of CIT in Italy, USD Millions (2017-2028)
  • Figure 28: Market Size of CIT by Therapies in USD Million (2017-2028)
  • Figure 29: Market Size of CIT in Spain, USD Millions (2017-2028)
  • Figure 30: Market Size of CIT by Therapies in USD Million (2017-2028)
  • Figure 31: Market Size of CIT in the United Kingdom, USD Millions (2017-2028)
  • Figure 32: Market Size of CIT by Therapies in USD Million (2017-2028)
  • Figure 33: Market Size of Chemotherapy-induced Thrombocytopenia in Japan, USD Millions (2017-2028)
  • Figure 34: Market Size of CIT by Therapies in USD Million (2017-2028)
  • Figure 35: Market Drivers
  • Figure 36: Market Barriers
Back to Top